Ainos Reports Q2 2025 Financials, Enters Commercial Execution Phase with AI Nose.

• Ainos reports Q2 2025 financial results • First senior care revenue generated • New strategic partnerships established • AI Nose roadmap targets 2H 2025 growth • First multi-year $2.1M order secured • Traction in robotics, semiconductors, and smart manufacturing • AI Nose commercial execution phase begins

Ainos, Inc. (NASDAQ:AIMD), a leading innovator in AI-driven scent digitization, has announced its financial results for the second quarter ended June 30, 2025. The company reported significant milestones, including the generation of its first senior care revenue, new strategic partnerships, and the commencement of the commercial execution phase for its AI Nose platform.

Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented on the quarter's achievements. "We're thrilled that our proprietary AI-powered scent digitization platform, AI Nose, has entered the commercial execution phase," said Tsai. "The first half of 2025 marked a strategic inflection point as we successfully transitioned from R&D to revenue-generating deployment in Japan."

The company secured its first three-year subscription order valued at $2.1 million with ASE Technology Holding Co., Ltd. (ASEH), a significant milestone in the semiconductor manufacturing sector. Additionally, Ainos has entered into strategic partnerships with industrial automation specialists and smart factory ecosystem partners, expanding its ecosystem and enhancing its scent database.

Christopher Lee, Chief Financial Officer of Ainos, highlighted the company's financial performance. "We're delighted with the strong momentum of our AI Nose platform, which drove significant first-half revenue growth through our co-development project in Japan's senior care sector," said Lee. "We also improved gross margin, turning to gross profitability in both Q2 and the first half."

Ainos' 90-day action plan for the second half of 2025 includes field tests with its robot customer in Japan and a multi-stage rollout roadmap with ASEH, targeting approximately 1,400 pilot deployments and then expanding to around 5,000 units. The company also plans to showcase its AI Nose-integrated robot with partners at Automation Taipei in late August and launch pilot programs across partners' target industrial sectors in Asia by the end of 2025.

Ainos continues to advance its VELDONA® immunotherapy programs, with two human clinical trials in Taiwan and promising interim results from its veterinary study in feline chronic gingivostomatitis (FCGS).

The company's strategic roadmap positions it for scale-up in 2026, with a focus on expanding AI Nose pilots, enriching its Smell ID dataset, and driving adoption across key verticals. As demand for intelligent environmental sensing accelerates, Ainos is uniquely positioned to provide the missing link and lead the next frontier of AI.

References:
[1] https://finance.yahoo.com/news/ainos-reports-second-quarter-2025-201500361.html